REVIEW ON SALES AND MARKETING

Shubham L. Ayanar*, Prof. Dnyaneshwar S. Vyavhare and Dr. Megha T. Salve

ABSTRACT

Pharmaceutical assiduity mechanics are changing at an inconceivable rate. Millions of bones are being spent in medicine discovery, which is followed by a rigorous clinical trial process leading up to the medicine administration agency's blessing to allow the medicine to hit the request. The medicine development process therefore has a typical cycle time of 10- 15 times. A great deal more is spent on selling these medicines to boost deals. The window of profitability lies only until the patent is alive after which general companies can manufacture and vend the same medicine. To maximize profit returns, medicine- marketing cycle needs to be more effective. Over the times, profit per deals person is falling and deals force effectiveness is reducing. While deals representatives are being added, the increase in profit is n't aligned to this cost. Companies are looking at enterprise to increase earnings without adding deals headcount, by reducing functional costs and other time-out. While utmost other sectors have taken up Business Intelligence and Performance Management drives more fluently Pharmaceutical enterprises have been a little reticent to embracing this arising technology. This whitepaper is intended to illustrate the eventuality that BIPM holds for pharmaceutical enterprises in the area of deals and marketing. In the pharmaceutical assiduity, known for its complexity and competition, effective deals and marketing are important to insure that croaker and cases are introduced to new medicines. This comprehensive review explores all aspects of deals and marketing in the pharmaceutical assiduity.

Keywords: Pharmaceutical deals strategies, Marketing tactics in the pharmaceutical assiduity, Deals performance in pharmaceutical companies, pharmaceutical deals force effectiveness.